# Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus

Shengfang Bao [ID] , Hua Huang, Yingying Jin, Fei Ding, Zhen Yang, Xuemei Xu, Chenxi Liu, Jingyi Lu, Yanliang Jin

Department of Rheumatology & Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

**Correspondence to**
Dr Yanliang Jin; jinyanliang@scmc.com.cn

## ABSTRACT

**Objective** To explore the clinical value of autoantibody-based subgroup framework and the trend of autoantibody fluctuation in juvenile-onset SLE (JSLE).

**Methods** Eighty-seven patients with JSLE were retrospectively collected and divided into subgroups via a two-step cluster based on the status of nine autoantibodies (double-stranded-DNA (dsDNA), nucleosome, histone, ribosomal P protein, Smith (Sm), u1-ribonucleoprotein (RNP), Sjögren's syndrome antigen A (SSA)/Ro52, SSA/Ro60, Sjögren's syndrome antigen B (SSB)/La). The final model selected in this study was based on adequate goodness of fit of the Silhouette coefficient and clinical interpretability. Clinical manifestations, organ involvements and disease activity were compared among the subgroups. Fluctuation in autoantibody status was also collected and analysed. Flare-free survival rates of the patients with positive/negative seroconversion and patients without seroconversion were studied by the Kaplan-Meier method and compared using a log-rank test.

**Results** Two clusters were identified: subgroup 1 (positive anti-Sm/RNP group) and subgroup 2 (negative anti-Sm/RNP group). There were more lupus nephritis (LN) and neuropsychiatric SLE (NPSLE) cases in subgroup 1 than in subgroup 2. Patients in subgroup 1 exhibited higher SLE Disease Activity Index scores compared with those in subgroup 2. Furthermore, anti-ribosomal P protein (61.1%), anti-nucleosome (58.3%) and anti-dsDNA (54%) were most commonly positive autoantibodies. A progressive decrease in the frequency of patients with positive results was demonstrated during the follow-up years. The decrease was notable for anti-dsDNA, anti-nucleosome and anti-ribosomal P protein (remaining 27.27%, 38.89% and 45.00% positive in the fifth year, respectively). While for those negative at baseline diagnosis, the decrease in the frequency of negative results was progressive but modest. Kaplan-Meier curve showed that the flare-free survival of patients with positive seroconversion was significantly lower than those without seroconversion and those with negative seroconversion (p<0.001).

**Conclusions** In children with SLE, subgroups based on autoantibody profile can be applied to differentiate phenotypes and disease activity. Two important organ involvements, LN and NPSLE, are more common in patients with positive anti-Sm/RNP autoantibodies. Positive seroconversion may provide a valuable perspective for assessing flare, and it is worthwhile to retest the array of autoantibodies during follow-up.

## WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Juvenile-onset SLE (JSLE) is characterised by multi-organ involvement with great variability and data are scarce in early ages. Meanwhile, there is an extensive heterogeneity and frequency of autoantibodies in SLE.

## WHAT THIS STUDY ADDS

⇒ It is the first time to report that in JSLE, subgroups based on autoantibody profile can be applied to differentiate phenotypes and disease activity. In addition, seroconversion can be observed overtime in patients with JSLE and help predict flare.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Subgroups of JSLE help in understanding the heterogeneity of clinical phenotypes and prognosis. Monitoring autoantibody seroconversion may provide information for flare.

## INTRODUCTION

SLE is a systemic autoimmune disease that can affect multiple organs and result in significant organ damage and failure.[1] Approximately 15%~20% of patients with SLE develop the disease before their 18th birthday and are therefore diagnosed with juvenile-onset SLE (JSLE).[2] JSLE is characterised by multiorgan impairments with great variability and with scarce data in early ages. Although advances in the management of JSLE have led to a remarkable improvement in the survival of patients, severe organ involvement or flare over time still leads to unfavourable outcomes.[3] Therefore, to judge prognosis and determine medication, further study in JSLE is of great clinical significance.

There is an extensive heterogeneity and frequency of autoantibodies in SLE. Therefore, the diagnostic entities in SLE are delineated by sets of consensus criteria.[1] In order to improve the understanding of underlying pathogenesis, diagnostics and disease prognosis, prior findings suggest that subgroups

can be identified on the basis of the autoantibody profile in adult SLE and distinct autoantibody-defined phenotypes may exist.[4–6]

Furthermore, autoantibodies do fluctuate during treatment in the setting of adult lupus.[7 8] However, the clinical relevance of indirect immunofluorescence-ANA (IF-ANA) seroconversion remains uncertain. To our knowledge, no studies have investigated subgroups based on autoantibodies and longitudinal seroconversion in JSLE before. Therefore, this study aimed to evaluate autoantibody-based subgroup framework and to examine the clinical value of autoantibody fluctuation in JSLE.

## METHODS

### Study population

We conducted a retrospective study of 89 children with SLE who were diagnosed in the Department of Rheumatology & Immunology at Shanghai Children's Medical Center from January 2016 to August 2022. Two patients with incomplete medical charts were excluded. There were 87 patients (9 males and 78 females) for final analysis. The mean age at diagnosis was 11.71±2.93 years (range: 2.75~17.75 years).

Twenty-one (21 of 87, 24.14%) cases were in the prepubertal period (≤7 years) at diagnosis, 52 of 87 (59.77%) in peri-pubertal (8~13 years) and 14 of 87 (16.09%) in the adolescent age group (14~18 years). All patients fulfilled the American College of Rheumatology (ACR) criteria, with disease onset at ages before 18 years.

### Two-step cluster analysis

Two-step cluster, an approach for exploring empirical groups of individuals with similar characteristics, is free hypothesis and uses the log-likelihood distance measure.[9] The Schwarz Bayesian Information Criterion and the large ratio of distance measures are considered to automatically select the optimal number of clusters.[9] The final model selected in this study was testified with adequate goodness of fit of the Silhouette coefficient and clinical interpretability.[10]

Silhouette coefficient is a cohesion and separation index which measures how similar individuals are to their cluster compared with other clusters (values >0.50 are interpreted as good fitting, between 0.30 and 0.50 as fair, and <0.30 as poor).[10]

As shown in online supplemental figure 1, a two-step cluster based on status of nine autoantibodies (double-stranded-DNA (dsDNA), nucleosome, histone, ribosomal P protein, Smith (Sm), u1-ribonucleoprotein (RNP), Sjögren's syndrome antigen A (SSA)/Ro52, SSA/Ro60, Sjögren's syndrome antigen B (SSB)/La) was performed, and two clusters (subgroups) were identified (Silhouette=0.4).

When anti-cardiolipin (CL) immunoglobulin (IgG/IgM) and anti-β2 glycoprotein I (β2GP1) IgG were included together in the model, the average Silhouette



**A**



**B**

**Figure 1** (A) Flow chart of 87 patients with JSLE. A cross-sectional research part with cluster analysis to understand the heterogeneity of clinical phenotypes. A longitudinal research part of 72 patients to evaluate autoantibody seroconversion. (B) Schematic of the study about how the seroconversion relates or not to flare. JSLE, juvenile-onset SLE.

was 0.3, lower than 0.4, so these three antiphospholipid (aPL) antibodies were not included here finally.

### Autoantibody data collection

We collected fluctuation in autoantibody status during follow-up in databases. Clinical manifestations were documented at the same time point as the autoantibody determination. An autoantibody test was considered positive in a patient if positive on ≥2 different occasions. The same was true for a negative result. Antibodies were detected by double immunodiffusion (DID). All tests were performed when blood was drawn according to standard protocol in the department.

aPL antibodies, including anti-CL IgG/IgM and anti-β2GP1 IgG, were analysed in the serum by ELISA, with aPL cut-off levels for positivity corresponding to the 99th percentile of the normal population.[6]

Four different autoantibody data patterns were observed for each autoantibody:[8] (1) always negative; (2) always positive; (3) negative at diagnosis with subsequent positive tests (positive seroconversion) and (4) positive at diagnosis with subsequent negative tests (negative seroconversion).

### Autoantibody seroconversion

Seventy-two patients had regular follow-up records at an interval of 1~6 months during the study period and they had at least two visits with autoantibody results in the longitudinal cohort (figure 1A).

The baseline period and index period were defined as 6 months before and 1 year after seroconversion, respectively (figure 1B). To reduce the effects of baseline high disease activity on the subsequent disease flares in the index period, we excluded patients with flares at baseline.

**Table 1** Characteristics of patients with positive/negative seroconversion and patients without seroconversion at the time of seroconversion or visits

| | Positive conversion cases n=20 | Negative conversion cases n=24 | Patients without seroconversion n=28 | P value |
|---|---|---|---|---|
| Age | 13.89±1.97 | 13.86±2.11 | 13.65±1.99 | 0.902 |
| Gender (female, %) | 19 (95.0) | 22 (91.7) | 24 (85.7) | 0.542 |
| Disease duration (months) | 24.16±14.30 | 28.79±15.99 | 21.40±10.72 | 0.228 |
| Lupus nephritis, n (%) | 10 (50.0) | 5 (20.8) | 5 (17.9) | 0.032 |
| Prior daily prednisone* | 8.68±7.88 | 12.14±4.69 | 11.67±5.01 | 0.164 |
| Autoantibody seroconversion events (n) | | | / | |
| Anti-La/SSB | 2 (10.0%) | 4 (16.7%) | | |
| Anti-ribosomal P protein | 4 (20.0%) | 23 (95.8%) | | |
| Anti-dsDNA | 6 (30.0%) | 20 (83.3%) | | |
| Anti-Sm | 3 (15.0%) | 6 (25.0%) | | |
| Anti-u1-RNP | 6 (30.0%) | 9 (37.5%) | | |
| Anti-histone | 8 (40.0%) | 16 (66.7%) | | |
| Anti-nucleosome | 7 (35.0%) | 24 (100.0%) | | |
| Anti-Ro52/SSA | 6 (30.0%) | 5 (20.8%) | | |
| Anti-Ro60/SSA | 6 (30.0%) | 6 (25.0%) | | |
| Subgroup at diagnosis: anti-Sm/RNP subgroup, n (%) | 12 (60.0) | 8 (33.3) | 3 (10.7) | 0.001 |

*Prior daily prednisone: medications used during the baseline period until seroconversion/visits.
dsDNA, double-stranded DNA; RNP, ribonucleoprotein; Sm, Smith; SSA, Sjögren's syndrome antigen A; SSB, Sjögren's syndrome antigen B.

Patients who were treated with rituximab or plasma exchange within 1 year before negative seroconversion were also excluded.

We identified 20 patients with positive seroconversion, 24 patients with negative seroconversion and 28 patients without seroconversion (table 1).

### Statistical analysis

Continuous variables were expressed as mean±SD and median (range). Categorical variables were presented as an absolute number (frequency). Two-step cluster analysis was used to identify groups of patients with similar autoantibody profiles. The result of two clusters was interpretable and clinically meaningful. The clusters were referred to as disease subgroups in this study. Logistic regression was performed to assess the association between clinical variables and each subgroup, including sex and age at inclusion as covariables. To evaluate number (frequency), categorical variable comparisons were first assessed by Pearson's $\chi 2$ test, which requires that at least 80% of the cells must have an expected frequency of ≥5 and no cell must have an expected frequency <1. Fisher's exact test (n≤5) was used. Flare-free survival rates of the patients with positive/negative seroconversion and patients without seroconversion were studied by the Kaplan-Meier method and compared using a log-rank test. All statistical analyses were performed using the SPSS V.26.0. The

statistical tests were two sided and a p<0.05 was considered statistically significant.

## RESULTS

### Subgroups defined by autoantibody status

Two-step cluster analysis based on autoantibody status grouped patients with JSLE into two subgroups (table 2).

Subgroup 1 (n=31, 35.6%) was dominated by positive anti-Sm/RNP, and subgroup 2 (n=56, 64.4%) was characterised by negative anti-Sm/RNP.

There were no significant differences in age and gender at baseline. There were more lupus nephritis (LN) and neuropsychiatric SLE (NPSLE) cases in subgroup 1 than in subgroup 2. Cases in subgroup 1 exhibited higher SLE Disease Activity Index (SLEDAI) scores compared with subgroup 2 at diagnosis. There were no significant differences in serositis, arthritis or mucocutaneous diseases (malar rash, discoid lupus, alopecia and oral ulcers) (table 3).

### ANA fine specificities and organ involvements

Association between autoantibodies and organ involvements is presented in online supplemental table 1. Among the ANA fine specificities, positive anti-dsDNA, anti-histone and anti-nucleosome were associated with LN. Positive anti-ribosomal P protein was associated with

**Table 2** Characteristics of autoantibody pattern in JSLE subgroups at diagnosis

| | Subgroup 1 n=31 (35.6%) | Subgroup 2 n=56 (64.4%) |
|---|---|---|
| Anti-Sm | 22 (71.0%) | 0 (0.0%) |
| Anti-u1-RNP | 31 (100.0%) | 0 (0.0%) |
| Anti-dsDNA | 23 (74.2%) | 31 (55.4%) |
| Anti-nucleosome | 22 (71.0%) | 27 (48.2%) |
| Anti-ribosomal P protein | 22 (71.0%) | 26 (46.4%) |
| Anti-histone | 21 (67.7%) | 27 (48.2%) |
| Anti-Ro52/SSA | 20 (64.5%) | 14 (25.0%) |
| Anti-Ro60/SSA | 24 (77.4%) | 16 (28.6%) |
| Anti-La/SSB | 7 (22.6%) | 11 (19.6%) |
| Anti-CL IgG | 8 (25.8%) | 3 (5.36%) |
| Anti-CL IgM | 6 (19.4%) | 2 (3.57%) |
| Anti-β2GP1 IgG | 8 (25.8%) | 3 (5.36%) |

CL, cardiolipin; dsDNA, double-stranded DNA; JSLE, juvenile-onset SLE; RNP, ribonucleoprotein; Sm, Smith; SSA, Sjögren's syndrome antigen A; SSB, Sjögren's syndrome antigen B; β2GP1, β2 glycoprotein I.

NPSLE. No significant difference was found in the other ANA fine specificities with organ involvements.

## ANA staining patterns

All patients fulfilled the ACR-1997 criteria[11] with IF-ANA positive at diagnosis (n=87, 100%). The distribution of staining patterns was detailed according to the International Consensus on ANA Patterns nomenclature. There were homogeneous (H, AC-1) (n=41, 47.13%), speckled (S, AC-4) (n=40, 45.98%), homogeneous/speckled (AC-1/4) (n=6, 6.90%) at diagnosis.

The majority of patients (n=75, 86.21%) kept their type of staining pattern during follow-up. The switched pattern was all found in subgroup 1. Twelve cases with H (13.79%) switched patterns at least once. Among them, nine cases with H switched to S and three cases with H switched to a dense, fine-speckled pattern (AC-2).

Decreasing IF-ANA titres were found in 55 cases (63.22%). Increasing IF-ANA titres were found in 15 cases (17.24%). Titres remained in 17 cases (19.54%).

Two patients in subgroup 1 (2 of 31, 6.45%) lost ANA positivity over time. The initial ANA titres of these two cases were in the range of 320. One had LN (International Society of Nephrology/Renal Pathology Society: IV+V), and the other had macrophage activation syndrome at diagnosis. Both were prescribed antimalarials, steroid and cyclophosphamide, one in combination with rituximab. At month 8, when data from two cases were available, they were IF-ANA negative and stayed negative during the follow-up.

## Autoantibody occurrence and seroconversions

All patients were ever positive regarding ≥1 of the analysed SLE-related fine specificity autoantibodies. Fifteen patients with incomplete autoantibody follow-up data were excluded. Online supplemental table 2 illustrates the prevalence of IF-ANA fine specificities and the number of patients seroconverting for each autoantibody specificity. Antibodies, which were ever positive and most stable over time, included anti-Ro52/SSA, Ro60/SSA, La/SSB, Sm and u1-RNP.

Anti-ribosomal P protein (n=44, 61.1%), anti-nucleosome (n=42, 58.3%) and anti-dsDNA (n=39, 54.2%) were most commonly autoantibodies positive at least once during follow-up. Over half of these cases seroconverted from positive to negative (online supplemental table 2).

The time to negative and positive seroconversion is shown in online supplemental table 3A,B.

Among patients with JSLE positive for each autoantibody at diagnosis, a progressive decrease in the frequency of patients with positive results was demonstrated during the follow-up years. The decrease was notable for anti-dsDNA, anti-nucleosome and anti-ribosomal P protein (remaining 27.27%, 38.89% and 45.00% positive in the fifth year, respectively) (figure 2A). Meanwhile, for those negative at diagnosis, the decrease in the frequency of negative results was progressive but modest (figure 2B).

**Table 3** Clinical manifestations in each JSLE subgroup at diagnosis

| | Subgroup 1 n=31 (35.6%) | Subgroup 2 n=56 (64.4%) | P value | HR | OR (95% CI) |
|---|---|---|---|---|---|
| Age | 10.98±2.79 | 11.91±3.72 | 0.228 | 1.085 | 0.950~1.239 |
| Gender (female, %) | 28 (90.3) | 50 (89.3) | 0.879 | 1.120 | 0.260~4.828 |
| SLEDAI | 15.85±4.51 | 12.81±6.29 | 0.035 | 1.102 | 1.007~1.207 |
| Mucocutaneous diseases | 23 (74.2%) | 43 (76.8%) | 0.787 | 1.515 | 0.417~3.177 |
| Lupus nephritis | 17 (54.8%) | 16 (28.6%) | 0.017 | 3.036 | 1.216~7.576 |
| Neuropsychiatric lupus | 15 (48.4%) | 7 (12.5%) | 0.001 | 6.562 | 2.274~18.940 |
| Serositis | 8 (25.8%) | 11 (19.6%) | 0.506 | 1.423 | 0.563~4.026 |
| Arthritis | 11 (35.4%) | 11 (19.6%) | 0.108 | 2.250 | 0.838~6.042 |

JSLE, juvenile-onset SLE; SLEDAI, SLE Disease Activity Index.

Figure 2 (A) Decrease in the percentage of patients with JSLE remaining positive for autoantibodies within 5 years (patients with an initial positive test result at the first visit were analysed). (B) Decrease in the percentage of patients with JSLE remaining negative for autoantibodies within 5 years (patients with an initial negative test at the first visit result were analysed). dsDNA, double-stranded DNA; JSLE, juvenile-onset SLE; RNP, ribonucleoprotein; Sm, Smith; SSA, Sjögren's syndrome antigen A; SSB, Sjögren's syndrome antigen B.

In two cases in this study, positive seroconversion of anti-Sm/RNP happened at 3 years after the first diagnosis of JSLE, followed by the occurrence of newly onset LN at the fifth year's follow-up.

Concordance of ANA fine specificities was observed. Thirty-seven patients had Ro52/SSA and/or Ro60/SSA antibodies, overlapping in 30 cases. Ten of 11 anti-La/SSB-positive patients were also positive with anti-Ro52/SSA and Ro60/SSA. Co-occurrence was also observed for antibodies against Sm and u1-RNP, whereas isolated appearance was only found for anti-u1-RNP (n=9). The presence of anti-histone (n=39) mainly overlapped with anti-dsDNA; only five cases were not anti-dsDNA positive.

### Autoantibody seroconversions and flare
Kaplan-Meier curve showed that the flare-free survival of patients with positive seroconversion was significantly lower than those without seroconversion and those with negative seroconversion (p<0.001) (figure 3).

### DISCUSSION
Accurate assessment of disease status is important for the management of JSLE.[12] Through analysis of autoantibody-based subgroups and longitudinal seroconversion, a deeper understanding of JSLE can be attained. We found differences existed in clinical manifestations and disease activity in the subdivision of JSLE based on



| | 3m | 6m | 9m | 12m | P(vs Cases without Seroconversion) |
|---|---|---|---|---|---|
| Cases with Negative Seroconversion | 24 (100.0%) | 23 (95.8%) | 22 (91.7%) | 19 (79.2%) | 0.179 |
| Cases with Positive Seroconversion | 10 (50.0%) | 4 (20.0%) | 2 (10.0%) | 0 (0%) | < 0.001 |
| Cases without Seroconversion | 24 (85.71%) | 23 (82.14%) | 19 (67.86%) | 18 (64.29%) | |

Figure 3 Lupus flare-free survival curve of seroconversion or visits. Kaplan-Meier curve of patients from three groups within the index period (flare: defined by SELENA-SLEDAI Flare Index). SLEDAI, SLE Disease Activity Index.

autoantibodies. Seroconversion overtime was common in JSLE. Negative seroconversion rates were rather frequent for anti-DNA antibodies, while anti-Ro/La antibodies were relatively persistent. Positive seroconversion existed and may be followed by flare.

IF-ANA has a capital role and serves as an entry criterion in the 2019 SLE classification criteria from the European Alliance of Associations for Rheumatology and ACR,[1] but data on switched patterns and titre fluctuation were scarce. The distribution in the present study was dominated by homogeneous (H, AC-1) (n=41, 47.13%) and speckled (S, AC-4) (n=40, 45.98%) at diagnosis, similar to that found in previous SLE cohorts.[8 13] The switched pattern from H to S was found and decreasing IF-ANA titres were observed during follow-up. According to the previous study, anti-DNA and anti-nucleosome antibodies produced by plasmablasts lead to the H staining, whereas anti-RNP antibodies generated by long-lived plasma cells, less susceptible to conventional immunosuppressive therapy, lead to the S pattern.[14] We also found that negative seroconversion rate was rather frequent for anti-nucleosome and anti-dsDNA. Thus, it seems that the switched pattern from H to S during treatment may be related to the easier elimination of the plasmablasts than the long-lived plasma cells in the bone marrow.[14] However, the staining pattern was stable overtime in the majority of our cases (84.21%). Furthermore, both the pattern and titres were not correlated with SLEDAI scores, in agreement with prior studies.[8] This finding may be related to the impact of various autoantibodies on ANA staining patterns and titres.[14 15] Thus, evaluating IF-ANA staining patterns and titres may not be helpful during follow-up and could not be applied to evaluate the disease activity of JSLE. It seems that the analysis of ANA fine specificities is an essential complement to the IF-ANA study.

Through two-step cluster analysis with autoantibody-defined phenotypes, our study showed that the cases

could be categorised based on autoantibody-defined phenotypes and the subgroups bear differential patterns of clinical manifestations in JSLE. Two important organ impairments, LN and NPSLE, differed between the groups at diagnosis. SELENA-SLEDAI scores in subgroup 1 were significantly higher than in subgroup 2. The phenomenon of renal involvement and lower SELENA-SLEDAI in the anti-nucleosome/Sm/DNA/RNP group was also put forward among adults with SLE.[6] This may be explained by the results that positive anti-dsDNA, anti-histone and anti-nucleosome were associated with LN. Furthermore, the higher prevalence of LN found in the anti-Sm/RNP group corresponded with previous studies.[4 6] On the other hand, positive anti-ribosomal P protein was associated with NPSLE. In addition, more positive seroconversion events were observed in subgroup 1 than in subgroup 2. Therefore, the division of the JSLE into distinct disease subsets may help to predict important organ involvement and to further design treatment strategies.

The cluster of SLE on the basis of antibodies varied from studies.[4 6] This may be due to the different onset of disease, population and experimental methods of testing the antibodies. The final model selected in this study was based on adequate goodness of fit of the Silhouette coefficient and clinical interpretability. In our study, aPL antibodies were not included in the final cluster analysis. This may be related to the small sample size. According to previous studies, the prevalence of SLE with positive aPL antibodies varies from 20% to 50% in adult patients with SLE and from 11% to 87% in patients with JSLE (depending on different aPL subtypes and study cohorts), though aPL syndrome is rare.[16 17] However, the interplay between aPLs and JSLE remains uncertain. Prior research of aPL analysis in patients with JSLE did not include the other autoantibodies, and thus the results may not be convincing enough because the impact of the other autoantibodies was neglected in the disease course.[18–20] Further studies with the increasing sample size and the prospective design will be necessary.

Most measurements of subdivisions based on autoantibodies were performed in a cross-sectional design.[6] However, autoantibodies vary over time. To our knowledge, seroconversion study for JSLE was scare. In our study, two cases (2.63%) lost ANA positivity over time. Ever-positive rate (15.3%–61.1%, respectively, depending on autoantibody specificity) and seroconversion rates fell within the range of prior findings detected by ELISA,[8] a more sensitive technique than DID. Thus, the fluctuation in this study was not a consequence of the low sensitivity of the DID assay. From a practical point of view, it is worthwhile to validate fluctuation by DID, a widely used assay, during follow-up.

Our study found that negative seroconversion rate was rather frequent for anti-nucleosome (57.1%) and anti-dsDNA (51.3%). The same phenomenon was found among adults with SLE.[7 8] It may be related to their origin from newly generated plasmablasts that require proliferation for their differentiation and maintenance,[14] and

therefore, are more susceptible to immunosuppressive therapy. On the other hand, the relatively persistent expression pattern of anti-Ro/La/RNP/Sm antibodies was considered to be related to their origin from long-lived plasma cells in the bone marrow.[14] As a result of the less frequent seroconversion rate of anti-Ro/La/RNP/Sm antibodies, whether it is necessary or cost-effective to repeat testing for these antibodies against extractable nuclear antigens (anti-ENA), remains controversial.[21] However, anti-Ro/ SSA and anti-dsDNA co-positivity was recently reported to be associated with progression to end-stage renal disease in juvenile LN,[22] suggesting the necessity to retest anti-Ro/SSA regardless of its relatively low seroconversion rate. Furthermore, the higher prevalence of LN found in the anti-Sm/RNP group corresponded with previous studies.[4 6] Therefore, analysis of serological conservations of both anti-DNA and anti-ENA may provide some information for assessing and guiding treatment, despite different conservation rates among autoantibodies.[23]

Although not as frequent as negative seroconversion, we found that the phenomenon of positive seroconversion still existed (negative seroconversion rates: 16.1%~57.1% vs positive seroconversion rates: 9.1%~19.4% of cases, respectively, depending on autoantibody specificity). The median interval to positive seroconversion varied from 2 to 5 years for the nine autoantibodies. In two cases of our study, positive seroconversion of anti-RNP/Sm happened 3 years after the first diagnosis of JSLE, followed by the occurrence of newly onset LN at the fifth year's follow-up. This finding of the production of IgG autoantibodies several years before organ involvement may be concordant with the prior study by Arbuckle et al[24] that ANA fine specificities were reported to be detected several years before the symptoms of SLE onset. The phenomenon was considered to be related to the years auto-reactive B cell needed to mature through episodic exposure to immunogenic autoantigens.[25] On the other hand, for patients already diagnosed with JSLE, we found that flare-free survival of patients with positive seroconversion was significantly lower than those without seroconversion and those with negative seroconversion. Therefore, it is worthwhile to retest the array of autoantibodies during follow-up, and positive seroconversion may provide a valuable perspective for assessing flare.

The limitations of our study were as follows. First, the size of our cohort was small. We will increase the sample size in future study. A prospective study will be necessary. Second, quantitative detection through ELISA will be applied, and autoantibody titres will be gathered and analysed. Third, due to the retrospective study design, there was an absence of the British Isles Lupus Assessment group index (BILAG) or the Systemic Lupus International Collaborating Clinics damage index (SDI), genomic variants[26] and serological data, such as cytokines.[27] Appropriate advanced biomarkers[28] may be introduced in further study to provide more insights into the pathogenic mechanisms of JSLE. Nevertheless, our study

shed light on better understanding of JSLE subpheno-types and seroconversions.

**ORCID iD**
Shengfang Bao http://orcid.org/0000-0001-5529-135X

## REFERENCES

1 Aringer M, Costenbader K, Daikh D, *et al*. 2019 European League against rheumatism/american College of rheumatology classification criteria for systemic lupus erythematosus. *Arthritis Rheumatol* 2019;71:1400–12.
2 Massias JS, Smith EMD, Al-Abadi E, *et al*. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. *Lupus* 2020;29:474–81.
3 Oni L, Wright RD, Marks S, *et al*. Kidney outcomes for children with lupus nephritis. *Pediatr Nephrol* 2021;36:1377–85.
4 To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? *Arthritis Rheum* 2005;52:4003–10.
5 Lewis MJ, McAndrew MB, Wheeler C, *et al*. Autoantibodies targeting TLR and smad pathways define new subgroups in systemic lupus erythematosus. *J Autoimmun* 2018;91:1–12.
6 Diaz-Gallo L-M, Oke V, Lundström E, *et al*. Four systemic lupus erythematosus subgroups, defined by autoantibodies status, differ regarding HLA-DRB1 genotype associations and immunological and clinical manifestations. *ACR Open Rheumatol* 2022;4:27–39.
7 Faria AC, Barcellos KSA, Andrade LEC. Longitudinal fluctuation of antibodies to extractable nuclear antigens in systemic lupus erythematosus. *J Rheumatol* 2005;32:1267–72.
8 Frodlund M, Wetterö J, Dahle C, *et al*. Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease. *Clin Exp Immunol* 2020;199:245–54.
9 Nylund KL, Asparouhov T, Muthén BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. *Structural Equation Modeling: A Multidisciplinary Journal* 2007;14:535–69.
10 Rousseeuw PJ. Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. *Journal of Computational and Applied Mathematics* 1987;20:53–65.
11 Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997;40:1725.
12 Trindade VC, Carneiro-Sampaio M, Bonfa E, *et al*. An update on the management of childhood-onset systemic lupus erythematosus. *Paediatr Drugs* 2021;23:331–47.
13 Rodsaward P, Chottawornsak N, Suwanchote S, *et al*. The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients. *Asian Pac J Allergy Immunol* 2021;39.
14 Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. *Nat Rev Rheumatol* 2020;16:565–79.
15 Al-Mughales JA. Anti-nuclear antibodies patterns in patients with systemic lupus erythematosus and their correlation with other diagnostic immunological parameters. *Front Immunol* 2022;13:850759.
16 Tincani A, Andreoli L, Chighizola C, *et al*. The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. *Autoimmunity* 2009;42:257–9.
17 Groot N, de Graeff N, Avcin T, *et al*. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the share initiative. *Ann Rheum Dis* 2017;76:1637–41.
18 von Scheven E, Glidden DV, Elder ME. Anti-Beta2-Glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. *Arthritis Rheum* 2002;47:414–20.
19 Ahluwalia J, Singh S, Naseem S, *et al*. Antiphospholipid antibodies in children with systemic lupus erythematosus: a long-term clinical and laboratory follow-up status study from northwest India. *Rheumatol Int* 2014;34:669–73.
20 İlgen U, Yayla ME, Ateş A, *et al*. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus. *Lupus* 2018;27:665–9.
21 Raissi TC, Hewson C, Pope JE. Repeat testing of antibodies and complements in systemic lupus erythematosus: when is it enough? *J Rheumatol* 2018;45:827–34.
22 Sherman MA, Gunawardana A, Amirault JP, *et al*. Autoantibody cluster analysis in juvenile lupus nephritis. *Clin Rheumatol* 2022;41:2375–81.
23 Fava A, Guthridge C, Kheir J, *et al*. Autoantibody trajectories associate with classification and treatment response in lupus nephritis. *Arthritis Rheumatol* 2022;74.(suppl 9) Available: https://acrabstracts.org/abstract/autoantibody-trajectories-associate-with-classification-and-treatment-response-in-lupus-nephritis/
24 Arbuckle MR, McClain MT, Rubertone MV, *et al*. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. *N Engl J Med* 2003;349:1526–33.
25 Ma K, Du W, Wang X, *et al*. Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus. *Int J Mol Sci* 2019;20:23.
26 Soni C, Reizis B. Self-DNA at the epicenter of SLE: immunogenic forms, regulation, and effects. *Front Immunol* 2019;10:1601.
27 Oke V, Brauner S, Larsson A, *et al*. IFN-λ1 with th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE). *Arthritis Res Ther* 2017;19:139.
28 Greenan-Barrett J, Doolan G, Shah D, *et al*. Biomarkers associated with organ-specific involvement in juvenile systemic lupus erythematosus. *Int J Mol Sci* 2021;22:14.

## Supplementary table 1.  Association between antibodies and manifestations in JSLE

| | | Mucocutaneous | | | LN | | | NPSLE | | | Serositis | | | Arthritis | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Involved | Not Involved | $\chi^2$ | Involved | Not Involved | $\chi^2$ | Involved | Not Involved | $\chi^2$ | Involved | Not Involved | $\chi^2$ | Involved | Not Involved | $\chi^2$ |
| Anti-Ro52/SSA | Positive n(%) | 27 87.1% | 4 12.9% | 0.003 P=0.957 | 11 35.5% | 20 64.5% | 1.343 P=0.247 | 7 22.6% | 24 77.4% | 1.032 P=0.310 | 9 29% | 22 71% | 0.454 P=0.500 | 10 32.3% | 21 67.7% | 0.279 P=0.597 |
| | Negative n(%) | 39 86.7% | 6 13.3% | | 22 48.9% | 23 51.5% | | 15 33.3% | 30 66.7% | | 10 19% | 35 57% | | 12 26.7% | 33 73.3% | |
| Anti-Ro60/SSA | Positive n(%) | 34 94.4% | 2 5.6% | 2.311 P=0.128 | 15 41.7% | 21 58.3% | 0.086 P=0.770 | 8 22.2% | 28 77.8% | 1.504 P=0.220 | 11 30.6% | 25 69.4% | 1.126 P=0.289 | 10 27.8% | 26 72.2% | 0.045 P=0.831 |
| | Negative n(%) | 32 80% | 8 20% | | 18 45% | 22 55% | | 14 35% | 26 65% | | 8 19% | 32 57% | | 12 30% | 28 70% | |
| Anti-La/SSB | Positive n(%) | 8 72.7% | 3 27.3% | 2.242 P=0.134 | 5 45.5% | 6 54.5% | 0.022 P=0.883 | 2 18.2% | 9 81.8% | 0.242 P=0.623 | 5 45.5% | 6 54.5% | 1.736 P=0.188 | 4 36.4% | 7 63.6% | 0.052 P=0.820 |
| | Negative n(%) | 58 89.2% | 7 10.8% | | 28 43.1% | 37 56.9% | | 20 30.8% | 45 69.2% | | 14 21.5% | 51 78.5% | | 18 27.7% | 47 72.3% | |
| Anti-Sm | Positive n(%) | 21 95.5% | 1 4.5% | 1.089 P=0.297 | 10 45.5% | 12 54.5% | 0.052 P=0.819 | 5 22.7% | 17 77.3% | 0.582 P=0.445 | 4 18.2% | 18 81.8% | 0.768 P=0.381 | 7 31.8% | 15 68.2% | 0.124 P=0.725 |
| | Negative n(%) | 45 66% | 9 16.7% | | 23 42.6% | 31 57.4% | | 17 31.5% | 37 68.5% | | 15 27.8% | 39 72.2% | | 15 27.8% | 39 72.2% | |
| Anti-u1RNP | Positive n(%) | 27 87.1% | 4 12.9% | 0.003 P=0.956 | 15 48.4% | 16 51.6% | 0.526 P=0.468 | 8 25.8% | 23 74.2% | 0.251 P=0.616 | 5 16.1% | 26 83.9% | 2.197 P=0.138 | 10 32.3% | 21 67.7% | 0.279 P=0.597 |
| | Negative n(%) | 39 86.7% | 6 13.3% | | 18 40% | 27 60% | | 14 31.3% | 31 68.9% | | 14 31.1% | 31 68.9% | | 12 26.7% | 33 73.3% | |
| Anti-dsDNA | Positive n(%) | 36 92.3% | 3 7.7% | 1.227 P=0.268 | 28 71.8% | 11 28.2% | 26.252 P<0.001* | 13 33.3% | 26 66.7% | 0.749 P=0.387 | 10 26.3% | 28 73.7% | 0.070 P=0.791 | 15 38.5% | 24 61.5% | 3.526 P=0.06 |
| | Negative n(%) | 30 81.1% | 7 18.9% | | 5 13.5% | 32 86.5% | | 9 24.3% | 28 75.7% | | 9 23.7% | 29 76.3% | | 7 18.9% | 30 81.1% | |
| Anti-ribosomal P protein | Positive n(%) | 35 79.5% | 9 20.5% | 3.471 P=0.062 | 17 38.6% | 27 61.4% | 0.974 P=0.324 | 18 40.9% | 26 59.1% | 7.27 P=0.007* | 10 22.7% | 34 77.3% | 0.288 P=0.592 | 11 25% | 33 75% | 0.792 P=0.374 |
| | Negative n(%) | 31 96.9% | 1 3.1% | | 16 50% | 16 50% | | 4 12.5% | 28 87.5% | | 9 28.1% | 23 71.9% | | 11 34.4% | 21 65.6% | |
| Anti-histone | Positive n(%) | 32 82.1% | 7 17.0% | 0.863 P=0.353 | 30 76.9% | 9 23.1% | 36.599 P<0.001* | 12 30.8% | 27 69.2% | 0.129 P=0.719 | 7 17.9% | 32 82.1% | 2.124 P=0.145 | 12 30.8% | 27 69.2% | 0.129 P=0.719 |

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

*Lupus Sci Med*

| | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Negative n(%) | 34 91.9% | 3 8.1% | | 3 8.1% | 34 91.9% | | 10 27% | 27 73% | | 12 32.4% | 25 67.6% | | 10 27% | 27 73% | |
| Anti-nucleosome | Positive n(%) | 34 81% | 8 19% | 1.814 P=0.178 | 30 71.4% | 12 28.6% | 29.976 P=0.001 * | 12 28.6% | 30 71.4% | 0.006 P=0.936 | 8 19% | 34 81% | 1.774 P=0.183 | 16 38.1% | 26 61.9% | 3.820 P=0.051 |
| | Negative n(%) | 32 94.1% | 2 5.9% | | 3 8.8% | 31 91.2% | | 10 29.4% | 24 70.6% | | 11 32.4% | 23 67.6% | | 6 17.6% | 28 82.4% | |

LN: Lupus Nephritis, NPSLE: Neuropsychiatric Systemic Lupus Erythematosus, *P < 0.05

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

*Lupus Sci Med*

**Supplementary table 2. Anti-nuclear antibody fine specificities over time among the 72 JSLE patients**

| | Ever positive, n(%) | Consistently positive, n(%) | Negative seroconversion, n(%) | Positive seroconversion, n(%) | Consistently negative, n(%) |
|---|---|---|---|---|---|
| Anti- Ro52/SSA | 31 43.1% | 20 64.5% | 5 16.1% | 6 19.4% | 41 56.9% |
| Anti- Ro60/SSA | 36 50.0% | 24 67% | 6 16.3% | 6 16.3% | 36 50.0% |
| Anti- La/SSB | 11 15.3% | 5 47% | 4 34.2% | 2 18.5% | 61 84.7% |
| Anti-Sm | 22 30.6% | 13 60% | 6 26.67% | 3 13.3% | 50 69.4% |
| Anti- u1RNP | 31 43.1% | 16 51.7% | 9 29.4% | 6 18.8% | 41 56.9% |
| Anti-dsDNA | 39 54.2% | 13 33% | 20 51.3% | 6 15.4% | 33 45.8% |
| Anti-ribosomal P protein | 44 61.1% | 17 39% | 23 52.3% | 4 9.1% | 28 38.9% |
| Anti-histone | 39 54.2% | 15 38% | 16 41.4% | 8 20.9% | 33 45.8% |
| Anti- nucleosome | 42 58.3% | 12 28.6% | 24 57.1% | 7 16.7% | 30 41.6% |

**Supplementary table 3a. Time to negative seroconversion among patients initially positive**

| | Time to Negative Seroconversion（months） | | | |
|---|---|---|---|---|
| | Mean±SD | Median | Minimum | Maximum |
| Anti-dsDNA | 16.65±15.53 | 11.0 | 1.00 | 60.00 |
| Anti- u1RNP | 28.58±22.35 | 36.0 | 2.00 | 60.00 |
| Anti-Sm | 24.44±20.19 | 24.0 | 2.00 | 60.00 |
| Anti- Ro52/SSA | 22.20±25.15 | 9.0 | 3.00 | 60.00 |
| Anti- Ro60/SSA | 28.58±22.35 | 20.5 | 6.00 | 60.00 |
| Anti- La/SSB | 12.25±13.32 | 7.0 | 3.00 | 32.00 |
| Anti- nucleosome | 16.73±15.97 | 9.0 | 2.00 | 60.00 |
| Anti-histone | 22.29±20.39 | 17.5 | 2.00 | 54.00 |
| Anti-ribosomal P protein | 23.91±16.64 | 21 | 3.00 | 60.00 |

Supplementary table 3b**. Time to positive seroconversion among patients initially negative**

| | Time to Positive Seroconversion（months） | | | |
|---|---|---|---|---|
| | Mean±SD | Median | Minimum | Maximum |
| Anti-dsDNA | 28.00±16.63 | 29.0 | 3.0 | 48.0 |
| Anti- u1RNP | 27.78±20.95 | 23.0 | 1.00 | 60.00 |
| Anti-Sm | 39.17±22.40 | 45.5 | 6.00 | 60.00 |
| Anti- Ro52/SSA | 34.17±21.29 | 40.5 | 1.00 | 60.00 |
| Anti- Ro60/SSA | 34.33±17.83 | 36.0 | 11.00 | 60.00 |
| Anti- La/SSB | 60.00 ±0.00 | 60.00 | 60.00 | 60.00 |
| Anti- nucleosome | 33.29±20.42 | 29.0 | 10.00 | 60.00 |
| Anti-histone | 35.13±23.05 | 36.0 | 3.00 | 60.00 |
| Anti-ribosomal P protein | 47.60±12.03 | 46.0 | 36.00 | 60.00 |